AI assistant
Sending…
Jasper Therapeutics, Inc. — Director's Dealing 2021
Oct 1, 2021
34406_dirs_2021-10-01_0fa5c1ed-3d65-4498-84d9-bea829bab4f2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Jasper Therapeutics, Inc. (JSPR)
CIK: 0001788028
Period of Report: 2021-09-24
Reporting Person: Nolet Chris (Director)
More from Jasper Therapeutics, Inc.
Annual Report
2026
Jun 15
Proxy Solicitation & Information Statement
2026
Jun 15
Proxy Solicitation & Information Statement
2026
Jun 15
Delisting Announcement
2026
Jun 9
Regulatory Filings
2026
Jun 1
Board/Management Information
2026
May 21
Interim / Quarterly Report
2026
May 14
Earnings Release
2026
May 14
Major Shareholding Notification
2026
Feb 12
Director's Dealing
2026
Feb 10